In March 2018 it was announce that Danaher would acquire Integrated DNA Techologies Inc. Integrated DNA Technologies, Inc. (IDT) develops and manufactures custom and synthetic DNA and RNA oligonucleotides for the research and diagnostic life science market worldwide. The company specializes in the areas of gene silencing based on RNAi, ddRNAi, and antisense technologies; transcription profiling; DNA sequencing; SNP detection; and DNA amplification. Its products include DNA/RNA synthesis and purifications; CRISPR genome editing; functional genomics; gene expression and genotyping products; products for fluorescence-based applications; roche/454 sequencing products; synthetic biology products; IVD and ASR oligos; nuclease control products; buffers and water markers; and readymade primers and products. The company also offers analytics services, such as custom preparative services, lab-ready oligo services, and mass spectrometry and CE services. In addition, it provides a range of services, including customer specified formulation, packaging, third party labeling, stability testing, and functional QC for third parties. The company's products are used in diagnostic tests for genetic diseases, such as breast cancer or cystic fibrosis; diagnostic tests for infectious diseases, including Hepatitis or AIDS; research to discover new drugs or treatments for various diseases; and producing agricultural products. It serves academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. Integrated DNA Technologies, Inc. was founded in 1987 and is headquartered in Coralville, Iowa. It has manufacturing locations and facilities in Coralville, Iowa; San Diego, California; Leuven, Belgium; and Singapore.
